Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Invesco Dynamic Pharmaceuticals ETF (PJP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: PJP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type ETF | Historic Profit 0.74% | Avg. Invested days 50 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Volume (30-day avg) 8335 | Beta 0.52 | 52 Weeks Range 74.52 - 89.34 | Updated Date 04/2/2025 |
52 Weeks Range 74.52 - 89.34 | Updated Date 04/2/2025 |
Upturn AI SWOT
Invesco Dynamic Pharmaceuticals ETF
ETF Overview
Overview
The Invesco Dynamic Pharmaceuticals ETF (PJP) is designed to provide investment results corresponding to the price and yield of the Dynamic Pharmaceuticals Intellidex Index. It focuses on companies involved in the research, development, manufacturing, and marketing of pharmaceuticals and drugs.
Reputation and Reliability
Invesco is a well-established and reputable asset management firm with a long track record in the ETF market.
Management Expertise
Invesco has a dedicated team of investment professionals with experience in managing sector-specific ETFs.
Investment Objective
Goal
To track the investment results, before fees and expenses, of the Dynamic Pharmaceuticals Intellidex Index.
Investment Approach and Strategy
Strategy: The ETF employs a full replication strategy, meaning it invests in all the securities of the underlying index in approximately the same proportions.
Composition The ETF primarily holds common stocks of US pharmaceutical companies.
Market Position
Market Share: PJP has a modest market share within the broader healthcare ETF landscape.
Total Net Assets (AUM): 88580000
Competitors
Key Competitors
- XBI
- IBB
- XLV
Competitive Landscape
The pharmaceutical ETF market is dominated by broader healthcare ETFs and biotech-focused ETFs. PJP differentiates itself through its dynamic methodology, which aims to identify companies with the strongest risk-return profiles, potentially leading to outperformance but also increased volatility compared to market-cap weighted competitors. PJP's smaller AUM may affect liquidity compared to larger competitors like XBI and IBB.
Financial Performance
Historical Performance: Historical performance data should be obtained from financial data providers.
Benchmark Comparison: Performance should be compared against the Dynamic Pharmaceuticals Intellidex Index.
Expense Ratio: 0.56
Liquidity
Average Trading Volume
PJP's average daily trading volume is relatively moderate, which may affect order execution costs for large trades.
Bid-Ask Spread
The bid-ask spread varies but typically is moderate, reflecting the ETF's trading volume.
Market Dynamics
Market Environment Factors
Factors such as FDA approvals, drug pricing regulations, patent expirations, and advancements in biotechnology significantly influence PJP's performance.
Growth Trajectory
PJP's growth is tied to the performance of the pharmaceutical sector, influenced by demographic trends, healthcare spending, and innovation in drug development. The fund's strategy is reviewed and holdings are dynamically adjusted.
Moat and Competitive Advantages
Competitive Edge
PJP's competitive advantage lies in its dynamic Intellidex methodology, which seeks to identify and weight companies with the greatest potential for capital appreciation. This approach differentiates it from passive, market-cap weighted ETFs in the pharmaceutical sector. The dynamic weighting may lead to higher returns during favorable market conditions, but it can also lead to greater volatility. However, the higher expense ratio compared to passive competitors could offset some of the benefits of the dynamic strategy.
Risk Analysis
Volatility
PJP's volatility can be relatively high due to its sector-specific focus and dynamic investment strategy.
Market Risk
PJP is subject to market risk associated with the pharmaceutical sector, including regulatory changes, clinical trial failures, and competition from generic drugs.
Investor Profile
Ideal Investor Profile
PJP is suitable for investors seeking targeted exposure to the pharmaceutical sector and willing to accept higher volatility for potential outperformance.
Market Risk
PJP is suitable for active traders and investors with a higher risk tolerance looking for sector-specific exposure, but less suited for passive index followers.
Summary
The Invesco Dynamic Pharmaceuticals ETF (PJP) offers targeted exposure to the US pharmaceutical sector through a dynamic Intellidex methodology. The ETF aims for capital appreciation by identifying companies with strong risk-return profiles. However, PJP's higher expense ratio and sector-specific focus may contribute to increased volatility compared to broader market ETFs. The ETF is best suited for investors with a higher risk tolerance seeking focused exposure to the pharmaceutical industry. Potential investors should carefully consider PJP's investment strategy and risk factors before investing.
Similar Companies
FXH
First Trust Health Care AlphaDEX® Fund
FXH
First Trust Health Care AlphaDEX® Fund
IBB
iShares Biotechnology ETF
IBB
iShares Biotechnology ETF
XBI
SPDR® S&P Biotech ETF
XBI
SPDR® S&P Biotech ETF
XLV
Health Care Select Sector SPDR® Fund
XLV
Health Care Select Sector SPDR® Fund
Sources and Disclaimers
Data Sources:
- Invesco.com
- Morningstar.com
- etfdb.com
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. Market share data is based on publicly available information and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invesco Dynamic Pharmaceuticals ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.